Key Points
- Director Juan Sanchez bought 13,000 shares at an average $5.79 on Nov. 5 for $75,270, increasing his stake 19.95% to 78,150 shares (≈$452,488).
- Nuvectis missed quarterly expectations with EPS of ($0.44) vs. a ($0.24) consensus, and the stock trades around $5.67 with a 50/200‑day MA of $6.21/$7.54 and a 52‑week range of $4.44–$11.80.
- Institutional ownership is very high (96.77%), and analysts are mixed — the consensus rating is "Moderate Buy" with a $15.33 target despite varied individual price targets and ratings.
Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) CEO Ron Bentsur purchased 5,000 shares of the firm's stock in a transaction that occurred on Wednesday, November 5th. The stock was acquired at an average price of $5.72 per share, with a total value of $28,600.00. Following the completion of the purchase, the chief executive officer owned 3,525,924 shares in the company, valued at $20,168,285.28. This represents a 0.14% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Nuvectis Pharma Stock Up 2.5%
Shares of NVCT stock traded up $0.14 during trading hours on Friday, hitting $5.81. 14,766 shares of the company's stock traded hands, compared to its average volume of 131,043. The stock has a market cap of $148.79 million, a price-to-earnings ratio of -4.22 and a beta of -0.28. Nuvectis Pharma, Inc. has a 12-month low of $4.44 and a 12-month high of $11.80. The stock's fifty day simple moving average is $6.21 and its two-hundred day simple moving average is $7.54.
Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.20). On average, equities analysts forecast that Nuvectis Pharma, Inc. will post -1.01 earnings per share for the current fiscal year.
Institutional Trading of Nuvectis Pharma
Institutional investors have recently made changes to their positions in the business. Police & Firemen s Retirement System of New Jersey bought a new position in Nuvectis Pharma in the 2nd quarter worth approximately $28,000. JPMorgan Chase & Co. boosted its position in shares of Nuvectis Pharma by 3,398.9% during the second quarter. JPMorgan Chase & Co. now owns 6,263 shares of the company's stock worth $47,000 after acquiring an additional 6,084 shares during the last quarter. Bank of America Corp DE boosted its position in shares of Nuvectis Pharma by 417.2% during the second quarter. Bank of America Corp DE now owns 8,565 shares of the company's stock worth $64,000 after acquiring an additional 6,909 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Nuvectis Pharma during the second quarter valued at $53,000. Finally, New York State Common Retirement Fund purchased a new stake in Nuvectis Pharma in the 2nd quarter worth $97,000. Hedge funds and other institutional investors own 96.77% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities analysts have issued reports on the stock. HC Wainwright lowered their target price on shares of Nuvectis Pharma from $15.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday, August 4th. Weiss Ratings restated a "sell (e+)" rating on shares of Nuvectis Pharma in a report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $15.33.
Check Out Our Latest Stock Analysis on NVCT
About Nuvectis Pharma
(
Get Free Report)
Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
